Skip to content

Ocular Therapeutix OCUL Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
Henry Schein logo
Henry ScheinHSIC

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's contract liabilities, non-current?
Ocular Therapeutix (OCUL) reported contract liabilities, non-current of $14M in Q1 2026.
How has Ocular Therapeutix's contract liabilities, non-current changed year-over-year?
Ocular Therapeutix's contract liabilities, non-current decreased by 0.0% year-over-year, from $14M to $14M.
What is the long-term trend for Ocular Therapeutix's contract liabilities, non-current?
Over 5 years (2020 to 2025), Ocular Therapeutix's contract liabilities, non-current has grown at a 3.1% compound annual growth rate (CAGR), from $12M to $14M.